Rapport Therapeutics (NASDAQ:RAPP) Director Wendy Young Buys 3,789 Shares of Company Stock

Rapport Therapeutics, Inc. (NASDAQ:RAPP) Director Wendy Young purchased 3,789 shares of the stock in a transaction that occurred on Thursday, October 22nd. The stock was purchased at an average price of $26.39 per share, for a total transaction of $99,991.71. Following the acquisition, the director owned 13,289 shares in the company, valued at approximately $350,696.71. This trade represents a 39.88% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.

Rapport Therapeutics Stock Up 5.9%

NASDAQ RAPP traded up $1.47 during mid-day trading on Thursday, hitting $26.53. The stock had a trading volume of 1,453,606 shares, compared to its average volume of 407,078. The company has a 50 day simple moving average of $39.86 and a 200 day simple moving average of $39.07. The company has a market cap of $1.27 billion, a price-to-earnings ratio of -8.73 and a beta of 1.22. Rapport Therapeutics, Inc. has a 52-week low of $23.75 and a 52-week high of $52.93.

Rapport Therapeutics (NASDAQ:RAPP) last posted its earnings results on Wednesday, August 5th. The company reported ($1.19) EPS for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.07). As a group, equities analysts anticipate that Rapport Therapeutics, Inc. will post -4.09 earnings per share for the current fiscal year.

Institutional Trading of Rapport Therapeutics

Several institutional investors have recently made changes to their positions in RAPP. Engineers Gate Manager LP purchased a new stake in shares of Rapport Therapeutics during the 2nd quarter valued at $888,000. Wellington Management Group LLP raised its position in shares of Rapport Therapeutics by 11.2% in the 2nd quarter. Wellington Management Group LLP now owns 86,988 shares of the company’s stock worth $3,625,000 after buying an additional 8,757 shares during the period. Artia Global Partners LP purchased a new position in shares of Rapport Therapeutics in the 2nd quarter worth $5,772,000. Bank of America Corp DE acquired a new position in Rapport Therapeutics in the second quarter valued at $3,170,000. Finally, Jupiter Topco LLC acquired a new position in Rapport Therapeutics in the second quarter valued at $574,000.

Analyst Ratings Changes

Several brokerages have issued reports on RAPP. TD Cowen reaffirmed a “buy” rating on shares of Rapport Therapeutics in a report on Tuesday. Wall Street Zen cut shares of Rapport Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Citigroup reissued an “outperform” rating on shares of Rapport Therapeutics in a research note on Tuesday. HC Wainwright restated a “buy” rating and set a $66.00 price objective on shares of Rapport Therapeutics in a research report on Tuesday. Finally, Guggenheim upped their target price on Rapport Therapeutics from $65.00 to $70.00 and gave the company a “buy” rating in a research note on Tuesday. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $68.36.

Key Headlines Impacting Rapport Therapeutics

Here are the key news stories impacting Rapport Therapeutics this week:

• Positive Sentiment: RAP-219 is advancing to Phase 3. Rapport said the drug met both Phase 2 endpoints in bipolar mania, producing statistically significant placebo-adjusted improvements in manic symptoms and overall illness severity. The results strengthen the potential value of RAP-219 and expand its development opportunity beyond epilepsy. Rapport plans Phase III bipolar mania trials
• Positive Sentiment: Analysts continue to raise or maintain bullish targets. JonesTrading increased its price target from $50 to $82 and maintained a Buy rating. BTIG Research also raised its target, while HC Wainwright reaffirmed its Buy rating. Raymond James recently set an $86 target and maintained Strong Buy. The analyst activity suggests Wall Street sees substantial upside if RAP-219 succeeds in later-stage development. BTIG Research price target update HC Wainwright rating update
• Positive Sentiment: CFO Troy Ignelzi bought 5,500 shares for $143,550. The purchase increased his direct holdings by 55% to 15,500 shares, a potentially supportive signal of management confidence. SEC insider ownership filing
• Neutral Sentiment: The clinical results move RAP-219 toward Phase 3 but do not eliminate biotechnology risks, including trial execution, regulatory approval, funding needs, and eventual commercialization.
• Negative Sentiment: Some coverage characterized the trial outcome as narrower than investors initially hoped. Rapport also remains unprofitable, recently reporting quarterly EPS below consensus, which could limit gains if future clinical or financial results disappoint. Rapport bipolar data analysis

Rapport Therapeutics Company Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for central nervous system disorders. The company’s approach is designed to selectively target receptor-associated proteins that regulate synaptic receptors, with the goal of improving therapeutic selectivity and reducing the side effects associated with broader-acting neurological medicines.

Rapport’s lead product candidate, RAP-219, is an orally administered small molecule being developed for neurological conditions, including focal epilepsy.